Russell Investments Group Ltd. Has $4.37 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE

Russell Investments Group Ltd. boosted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 15.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 120,195 shares of the biopharmaceutical company’s stock after purchasing an additional 16,373 shares during the period. Russell Investments Group Ltd. owned about 0.12% of Ultragenyx Pharmaceutical worth $4,370,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Rhenman & Partners Asset Management AB lifted its position in shares of Ultragenyx Pharmaceutical by 13.5% during the 2nd quarter. Rhenman & Partners Asset Management AB now owns 93,100 shares of the biopharmaceutical company’s stock worth $3,385,000 after buying an additional 11,100 shares during the period. XTX Topco Ltd raised its stake in Ultragenyx Pharmaceutical by 17.1% during the second quarter. XTX Topco Ltd now owns 37,220 shares of the biopharmaceutical company’s stock worth $1,353,000 after acquiring an additional 5,440 shares in the last quarter. American Century Companies Inc. bought a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at $366,000. Legal & General Group Plc boosted its stake in shares of Ultragenyx Pharmaceutical by 21.2% in the 2nd quarter. Legal & General Group Plc now owns 313,804 shares of the biopharmaceutical company’s stock valued at $11,410,000 after purchasing an additional 54,837 shares in the last quarter. Finally, DNB Asset Management AS boosted its stake in shares of Ultragenyx Pharmaceutical by 3.2% in the 2nd quarter. DNB Asset Management AS now owns 14,720 shares of the biopharmaceutical company’s stock valued at $535,000 after purchasing an additional 452 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Price Performance

RARE opened at $36.38 on Friday. The stock has a market capitalization of $3.51 billion, a P/E ratio of -6.12 and a beta of 0.16. The company’s 50 day simple moving average is $32.89 and its 200-day simple moving average is $32.39. Ultragenyx Pharmaceutical Inc. has a one year low of $25.81 and a one year high of $50.00.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.58). The firm had revenue of $159.93 million for the quarter, compared to analyst estimates of $167.42 million. Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.The firm’s quarterly revenue was up 14.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.40) EPS. As a group, analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Analysts Set New Price Targets

RARE has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $105.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, October 8th. Truist Financial cut their target price on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. TD Cowen decreased their price target on Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 9th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $80.23.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,942 shares of the business’s stock in a transaction dated Monday, October 13th. The stock was sold at an average price of $31.51, for a total transaction of $250,252.42. Following the completion of the sale, the chief financial officer directly owned 98,227 shares of the company’s stock, valued at approximately $3,095,132.77. The trade was a 7.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the company’s stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $31.17, for a total transaction of $76,366.50. Following the transaction, the executive vice president owned 73,271 shares in the company, valued at approximately $2,283,857.07. The trade was a 3.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 10,456 shares of company stock worth $328,486 in the last ninety days. 5.50% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.